Cullinan Therapeutics (CGEM) Income from Non-Controlling Interests: 2021-2023
Historic Income from Non-Controlling Interests for Cullinan Therapeutics (CGEM) over the last 2 years, with Dec 2023 value amounting to -$1.8 million.
- Cullinan Therapeutics' Income from Non-Controlling Interests fell 475.16% to -$1.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$2.3 million, marking a year-over-year decrease of 15.45%. This contributed to the annual value of -$192,000 for FY2024, which is 90.10% up from last year.
- As of Q4 2023, Cullinan Therapeutics' Income from Non-Controlling Interests stood at -$1.8 million, which was down 883.24% from -$179,000 recorded in Q1 2023.
- In the past 5 years, Cullinan Therapeutics' Income from Non-Controlling Interests registered a high of $1.5 million during Q1 2021, and its lowest value of -$1.8 million during Q4 2023.
- Moreover, its 3-year median value for Income from Non-Controlling Interests was -$798,500 (2021), whereas its average is -$586,200.
- In the last 5 years, Cullinan Therapeutics' Income from Non-Controlling Interests surged by 90.54% in 2022 and then plummeted by 475.16% in 2023.
- Quarterly analysis of 3 years shows Cullinan Therapeutics' Income from Non-Controlling Interests stood at -$1.7 million in 2021, then surged by 81.91% to -$306,000 in 2022, then crashed by 475.16% to -$1.8 million in 2023.
- Its last three reported values are -$1.8 million in Q4 2023, -$179,000 for Q1 2023, and -$306,000 during Q4 2022.